Skip to main content

Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.

We'd appreciate your feedback.Tell us what you think! opens in new tab/window

Elsevier
Publish with us
AI-Generated response:

Does lysine prevent HSV outbreaks?

Answer generated on June 4, 2024

The AI-generated responses are for illustration purposes only and should not be used for medical purposes.

Lysine may help in controlling herpes simplex virus outbreaks, but more studies are needed to confirm its efficacy and safety as a therapeutic option.[1]

  • Lysine is thought to interfere with the formation of viral capsid proteins and DNA through competitive antagonism with arginine, which is essential for some viruses.[1]

  • Increasing the catabolism of arginine by promoting the activity of arginase is another mechanism by which lysine might exert its antiviral effects.[1]

  • The evidence supporting the use of lysine in controlling viral infections, including herpes simplex, suggests a potential therapeutic property, but it is not conclusive.[1]

  • Current antiviral therapies do not affect viruses in their latent state but can interfere with viral adhesion, fusion, and protein production, which are crucial in the initial and reactivation phases of viral infections.[1]

  • Further research is necessary to establish lysine as a reliable and safe treatment option for herpes simplex virus outbreaks.[1]

Additional info

The narrative review by Pedrazini et al. highlights the biochemical interaction between lysine and arginine and its potential implications in viral control, specifically noting the competitive inhibition that might disrupt the viral lifecycle.[1] However, the review also emphasizes the need for more targeted studies to fully understand the therapeutic potential and safety profile of lysine in the treatment of viral infections such as herpes simplex. This information is crucial for clinicians considering lysine as part of a treatment strategy, as the current evidence does not yet fully support its use without reservations. Further clinical trials and research are needed to determine optimal dosing, potential side effects, and overall efficacy in preventing herpes outbreaks.

References

Reference 1

1.

Pedrazini MC, da Silva MH, Groppo FC. British Journal of Clinical Pharmacology. 2022;88(11):4708-4723. doi:10.1111/bcp.15444.

Publish date: November 2, 2022.

Knowledge about viral characteristics, mechanisms of entry into the host cell and multiplication/dissemination can help in the control and treatment of viral pathologies. Several nutritional factors linked to the host may favour viral multiplication and their control, may lead to new prophylactic alternatives and/or antiviral therapies. The objective of this review is to discuss the relationship between the amino acid L-lysine and the control of viral infections, aiming at a possible therapeutic property. This research used databases such as PubMed, Web of Science, Scielo, Medline and Google Scholar, as well as searching for references cited by journals. The time frame covered the period between 1964 and January 2022. The observed studies have shown that the usual antiviral therapies are not able to interfere with the viruses in their latent state; however, they can interfere with the adhesion and fusion of viral particles or the production of proteins, which play an important role in viral epidemiology and control, particularly in the initial moment and in reactivation. Lysine is an amino acid that can interfere mainly in the formation of capsid proteins and DNA by a competitive antagonism with amino acid arginine, which is an essential amino acid for some viruses, and also by promoting the increase of arginase, increasing the catabolism of arginine. Although there is evidence of the importance of L-lysine in viral control, more studies are needed, with a view to new antiviral therapies.

Follow up questions